Evaluation of miRNA-21-5p and miRNA-10b-5p levels in serum-derived exosomes of breast cancer patients in different grades. (August 2022)

• Record Type: Journal Article
• Authors: Asadirad, Ali; Khodadadi, Ali; Talaiezadeh, Abdolhassan; Shohan, Mojtaba; Rashno, Mohammad; Joudaki, Nazanin
• Is Part Of: Molecular and cellular probes. Volume 64(2022)
• Publication Date: 2022-08
• Subjects: Exosomes -- Breast cancer -- miRNA-21–5p -- miRNA-10b-5p -- Epithelial-mesenchymal transition; Molecular probes -- Diagnostic use -- Periodicals; Pathology, Cellular -- Technique -- Periodicals; Cell Biology -- Periodicals; Molecular Biology -- Periodicals; Sondes moléculaires -- Utilisation diagnostique -- Périodiques; Cytopathologie -- Technique -- Périodiques; 572
• DOI: 10.1016/j.mcp.2022.101831
• Languages: English
• ISSNs: 0890-8508

Abstract

Abstract: Background & objectives: Tumor cells have various effects and dominance over other healthy cells. Cancer cells alter the cell program in healthy cells by secreting exosomes containing microRNAs involved in epithelial-mesenchymal transition (EMT). They can migrate to distant organs and establish a pre-metastatic niche. The purpose of this study was to determine the expression of miRNA-21–5p and miRNA-10b-5p, both of which are involved in EMT, in breast cancer-derived exosomes of various grades in order to identify new biomarkers involved in breast cancer progression. Methods: In this study, a blood sample was taken from 60 patients with grades I, II, or III breast cancer, as well as twenty healthy individuals as a control group. The exosomes were then purified from serum samples, and their relative expression of miRNA-21–5p and miRNA-10b-5p was determined using the real-time PCR method. Results: miRNA-21–5p expression was significantly increased in patients with breast cancer grades I, II, and III compared to the control group (p < 0.01), (p < 0.0001) and (p < 0.0001), respectively, as was miRNA-10b-5p expression in patients with breast cancer grades I, II, and III compared to the control group (p < 0.0001), (p < 0.0001) and (p < 0.0001), respectively. Conclusion: Our results show that both microRNAs increase as cells lose their differentiation and become more invasive, which is evidence of cancer progression. Hence, both microRNAs may have the potential to be used alone or in combination with other biomarkers for the diagnosis and prognosis of breast cancer. Highlights: Increased expression of miRNA-21–5p and miRNA-10b-5p in serum-derived exosomes of breast cancer patients compared with healthy individuals. Increased expression of miRNA-21–5p and miRNA-10b-5p effective in the epithelial-mesenchymal transition process in serum-derived exosomes of breast cancer patients in different grades. miRNA-21–5p and miRNA-10b-5p are two new biomarkers in the diagnosis and monitoring of breast cancer.